Literature DB >> 19665608

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile.

Hanna Czajka1, Volker Schuster, Fred Zepp, Susanna Esposito, Martine Douha, Paul Willems.   

Abstract

Priorix-Tetra (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix) and varicella (Varilrix) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19665608     DOI： 10.1016/j.vaccine.2009.07.076

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

Review 2.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

3.  Statement on Measles-Mumps-Rubella-Varicella Vaccine: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.

Authors:  Ben Tan; Shainoor Ismail
Journal:  Can Commun Dis Rep       Date:  2010-09-21

Review 4.  Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses.

Authors:  Paolo Bonanni; Anne Gershon; Michael Gershon; Andrea Kulcsár; Vassiliki Papaevangelou; Bernard Rentier; Catherine Sadzot-Delvaux; Vytautas Usonis; Timo Vesikari; Catherine Weil-Olivier; Peter de Winter; Peter Wutzler
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

5.  Evaluation of the Bio-Rad BioPlex Measles, Mumps, Rubella, and Varicella-Zoster Virus IgG multiplex bead immunoassay.

Authors:  Matthew J Binnicker; Deborah J Jespersen; Leonard O Rollins
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 6.  Vaccines for measles, mumps and rubella in children.

Authors:  Vittorio Demicheli; Alessandro Rivetti; Maria Grazia Debalini; Carlo Di Pietrantonj
Journal:  Cochrane Database Syst Rev       Date:  2012-02-15

Review 7.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

8.  Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study.

Authors:  Shannon E MacDonald; Douglas C Dover; Kimberley A Simmonds; Lawrence W Svenson
Journal:  CMAJ       Date:  2014-06-09       Impact factor: 8.262

9.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

10.  Rubella outbreak in a Rural Kenyan District, 2014: documenting the need for routine rubella immunization in Kenya.

Authors:  Ian Njeru; Dickens Onyango; Yusuf Ajack; Elizabeth Kiptoo
Journal:  BMC Infect Dis       Date:  2015-06-27       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.